Introduction
Neurodegenerative disorders, such as Alzheimer disease (AD) and Parkinson disease (PD), are a heterogeneous group of disorders characterized by a progressive and selective loss of anatomically or physiologically related neuronal systems (Forman et al., 2004; Lang and Lozano, 1998; Rathmann and Conner, 1984; Skovronsky et al., 2006) . While the majority of these diseases affect patients later in life, abundant evidence suggests the existence of a "preclinical" stage that could start years before a subject can be diagnosed, where an individual appears normal but is developing extensive pathological changes in the brain (Litvan et al., 2007; Morris and Price, 2001) .
Although many neurodegenerative diseases cannot be cured at the present time, there are often symptomatic treatments available and new drugs are emerging to forestall and/or reverse the onset and/or progress of the diseases (Forman et al., 2004; Skovronsky et al., 2006) .
